https://ppr-antibioresistance.inserm.fr/fr/veille-scientifique/ceftolozane-tazobactam-versus-meropenem-for-treatment-of-nosocomial-pneumonia-aspect-np-a-randomised-controlled-double-blind-phase-3-non-inferiority-trial/
Ceftolozane-tazobactam Versus Meropenem for Treatment of Nosocomial Pneumonia (ASPECT-NP): A...
Feb 11, 2021 - Lancet Infect Dis • 2019.09.25
nosocomial pneumoniaceftolozanetazobactamversusmeropenem
https://www.openhealthgroup.com/insights/health-economic-evaluation-of-patients-treated-for-nosocomial-pneumonia-caused-by-methicillin-resistant-staphylococcus-aureus-secondary-analysis-of-a-multicenter-randomized-clinical-trial-of-vancomyc/
Health economic evaluation of patients treated for nosocomial pneumonia caused by...
Authors: M S Niederman, J Chastre, C T Solem, Y Wan, X Gao, D E Myers, S Haider, J Z Li, J M Stephens Published: Clinical Therapeutics, 2014 View publication...
economic evaluationnosocomial pneumoniahealthpatientstreated
https://www.infectioncontroltoday.com/view/infection-control-today-052003-fighting-nosocomial-pneumonia
Infection Control Today - 05/2003: Fighting Nosocomial Pneumonia | Infection Control Today
Oct 12, 2026 - Infection Control Today serves infection control, facility, and C-suite leaders with strategies on HAIs, patient care, safety, and quality outcomes
infection controlnosocomial pneumoniatodayfighting